

Minutes

Date Wednesday, 04/12/2024
Time 9:00 AM
To Committee Members
At Virtual via MS Teams
Subject AWERB 3Rs Committee
Our Ref Doc.AWERB.3Rs.04.12.24

AWERB 3Rs Committee : [REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

In attendance: [REDACTED]
[REDACTED]
[REDACTED]

Mentioned in text: [REDACTED]

Minutes – [REDACTED]

Apologies: [REDACTED]

1. Minutes

The minutes from the previous meeting held on 06/11/2024 were approved.

2. Matters arising

There were no matters arising from the meeting held on 06/11/2024.

3. Retrospective Reviews / Retrospective Assessments

(a) [REDACTED] - [REDACTED] - Development of Live Bacterial Therapeutics to treat diseases with intestinal dysbiosis – RR

The committee discussed the following:

- A review of the content needed in Section 2.2.
- Tissue sharing information to be reviewed in Section 2.7.
- Further explanation needed regarding non-animal alternatives not being used in Section 3.1.
- Additional information needed regarding tissue sharing in Section 3.3.
- Details of the progress made whilst holding this licence needed in Section 4.

(b) [REDACTED] - [REDACTED] - Development of Live Bacterial Therapeutics for the treatment of cancer – RR

The committee discussed the following:

- Further detail needed regarding the level of severity in Section 2.2.
- Clarification needed in Section 2.3 regarding the two animals listed in Section 2.1.
- Information to be completed in Section 3.1.
- Refinements to be clarified in Section 3.7.
- Details of the progress made whilst holding this licence needed in Section 4.
- SC18 reports to be submitted with the Retrospective Review and added to Section 5.2.

(c) [REDACTED] – [REDACTED] - Respiratory biology and pharmacology – RR

The committee discussed the following:

- Clarification needed regarding the statement in the first row of the table in Section 2.5
- Further Information regarding sharing in Section 3.
- Further information needed regarding the PPL text in Section 4.5.
- Further information needed in Section 4.7.

4. Project Licence Applications – New / Amendments

(a) [REDACTED] – Implications of therapeutic use of complement activation modifying monoclonal antibodies on infectious and non-infectious inflammatory diseases – New SS Application.

The committee discussed the following:

- Amendments needed to maintain consistency in Protocol 2, Step 1, part d.
- A review needed to clarify the timepoints at which the steps in the procedures ended in Protocol 2, Step 1. Additionally, focus needed around weight loss and permitted timeframes.
- Clarification needed regarding timings in Protocol 2, Step 1.
- Further detail needed regarding the necessity of the timings in step 1, Protocol 2.

5. Standard Condition 18 / 3Rs reports

[REDACTED] asked if anyone had any comments about the information circulated. [REDACTED] complemented the information from the [REDACTED] and [REDACTED] site visits. [REDACTED] asked if this information was going to be shared. [REDACTED] confirmed this information will be shared to a wider audience within the University. [REDACTED] informed the committee that [REDACTED] and the NIO's will be making time to visit every facility throughout the year. [REDACTED] credited a lot of the work to [REDACTED]. [REDACTED] found the information useful. Seeing how other facilities manage specific issues. [REDACTED] would like copies of the images as they would be useful when hosting school visits. It will help her explain how animals are used and why. [REDACTED] asked anyone with any questions to forward them to himself and [REDACTED].

6. Minutes of the AOC meeting

Minutes from the meeting held on 18/10/2024 were noted.

7. Minutes of the AWERB Standing meeting

The minutes from the most recent Standing meeting are not available currently.

8. Any Other Business

[REDACTED] informed the committee of the change to the 3Rs Chairperson. [REDACTED] has agreed to take on the role with [REDACTED] as additional support as deputy Chairperson. [REDACTED] thanked the [REDACTED] for his support over the years.

Date of next meeting: 08/01/2025 via MS Teams